The University of Southampton
University of Southampton Institutional Repository

The United Kingdom Infantile Spasms Study comparing hormone treatment with bigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial

The United Kingdom Infantile Spasms Study comparing hormone treatment with bigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial
The United Kingdom Infantile Spasms Study comparing hormone treatment with bigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial
Background: Infantile spasms is a severe infantile seizure disorder that is difficult to treat and has a high morbidity. Absence of spasms on days 13 and 14 after randomisation is more common in infants allocated hormone treatments than in those allocated vigabatrin. We sought to assess whether early control of spasms is associated with improved developmental or epilepsy outcomes.
Methods: Infants enrolled in the United Kingdom Infantile Spasms Study (UKISS) were randomly assigned hormone treatment (n=55) or vigabatrin (n=52) and were followed up until clinical assessment at 12–14 months of age. We assessed neurodevelopment with the Vineland adaptive behaviour scales (VABS) at 14 months of age on an intention to treat basis.
Findings: Of 107 infants enrolled, five died and 101 survivors reached both follow-up assessments. Absence of spasms at final clinical assessment (hormone 41/55 [75%] vs vigabatrin 39/51 [76%]) was similar in each treatment group (difference 1·9%, 95% CI ?18·3% to 14·4%; ?2=0·05; p=0·82). Mean VABS score did not differ significantly (hormone 78·6 [SD 16·8] vs vigabatrin 77·5 [SD 12·7]; difference 1·0, 95% CI ?4·9 to 7·0; t99=0·35, p=0·73). In infants with no identified underlying aetiology, the mean VABS score was higher in those allocated hormone treatment than in those allocated vigabatrin (88·2 [17·3] vs 78·9 [14·3]; difference 9·3, 95% CI 1·2 to 17·3; t95=2·28, p=0·025).
Interpretation: Hormone treatment controls spasms better than does vigabatrin initially, but not at 12–14 months of age. Better initial control of spasms by hormone treatment in those with no identified underlying aetiology may lead to improved developmental outcome.
712-717
Lux, A.L.
23148201-b83e-40d8-8111-3e77eca567fa
Edwards, S.W.
a99b02b7-b168-45cd-9733-5b043942b075
Hancock, E.
92fdbac5-4dbd-4961-954c-5820957ea897
Johnson, A.L.
cc9b8f94-8cde-4ce5-9cff-1902c4cd9693
Kennedy, C.R.
7c3aff62-0a86-4b44-b7d7-4bc01f23ec93
Newton, R.W. P'Callaghan.F.J.K.
e9ccb994-b2df-4217-872e-2db576645662
Verity, C.M.
c934d256-e064-4ded-a996-530cd79788e9
Osborne, J.P.
edc077a5-96df-4189-a3da-5bf63507101a
Lux, A.L.
23148201-b83e-40d8-8111-3e77eca567fa
Edwards, S.W.
a99b02b7-b168-45cd-9733-5b043942b075
Hancock, E.
92fdbac5-4dbd-4961-954c-5820957ea897
Johnson, A.L.
cc9b8f94-8cde-4ce5-9cff-1902c4cd9693
Kennedy, C.R.
7c3aff62-0a86-4b44-b7d7-4bc01f23ec93
Newton, R.W. P'Callaghan.F.J.K.
e9ccb994-b2df-4217-872e-2db576645662
Verity, C.M.
c934d256-e064-4ded-a996-530cd79788e9
Osborne, J.P.
edc077a5-96df-4189-a3da-5bf63507101a

Lux, A.L., Edwards, S.W., Hancock, E., Johnson, A.L., Kennedy, C.R., Newton, R.W. P'Callaghan.F.J.K., Verity, C.M. and Osborne, J.P. (2005) The United Kingdom Infantile Spasms Study comparing hormone treatment with bigabatrin on developmental and epilepsy outcomes to age 14 months: a multicentre randomised trial. The Lancet Neurology, 4 (11), 712-717. (doi:10.1016/S1474-4422(05)70199-X).

Record type: Article

Abstract

Background: Infantile spasms is a severe infantile seizure disorder that is difficult to treat and has a high morbidity. Absence of spasms on days 13 and 14 after randomisation is more common in infants allocated hormone treatments than in those allocated vigabatrin. We sought to assess whether early control of spasms is associated with improved developmental or epilepsy outcomes.
Methods: Infants enrolled in the United Kingdom Infantile Spasms Study (UKISS) were randomly assigned hormone treatment (n=55) or vigabatrin (n=52) and were followed up until clinical assessment at 12–14 months of age. We assessed neurodevelopment with the Vineland adaptive behaviour scales (VABS) at 14 months of age on an intention to treat basis.
Findings: Of 107 infants enrolled, five died and 101 survivors reached both follow-up assessments. Absence of spasms at final clinical assessment (hormone 41/55 [75%] vs vigabatrin 39/51 [76%]) was similar in each treatment group (difference 1·9%, 95% CI ?18·3% to 14·4%; ?2=0·05; p=0·82). Mean VABS score did not differ significantly (hormone 78·6 [SD 16·8] vs vigabatrin 77·5 [SD 12·7]; difference 1·0, 95% CI ?4·9 to 7·0; t99=0·35, p=0·73). In infants with no identified underlying aetiology, the mean VABS score was higher in those allocated hormone treatment than in those allocated vigabatrin (88·2 [17·3] vs 78·9 [14·3]; difference 9·3, 95% CI 1·2 to 17·3; t95=2·28, p=0·025).
Interpretation: Hormone treatment controls spasms better than does vigabatrin initially, but not at 12–14 months of age. Better initial control of spasms by hormone treatment in those with no identified underlying aetiology may lead to improved developmental outcome.

This record has no associated files available for download.

More information

Published date: 2005

Identifiers

Local EPrints ID: 27644
URI: http://eprints.soton.ac.uk/id/eprint/27644
PURE UUID: 61ce8c98-f605-4ae7-bd7a-4971a08020dc

Catalogue record

Date deposited: 26 Apr 2006
Last modified: 15 Mar 2024 07:20

Export record

Altmetrics

Contributors

Author: A.L. Lux
Author: S.W. Edwards
Author: E. Hancock
Author: A.L. Johnson
Author: C.R. Kennedy
Author: R.W. P'Callaghan.F.J.K. Newton
Author: C.M. Verity
Author: J.P. Osborne

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×